If you have a glioblastoma diagnosis, or you're a caregiver doing research, clinical trials may be on your list. They can give you access to treatments that aren't yet standard care. But a trial isn't a lottery. Each one is designed for a specific group of patients. Learning to read eligibility rules, judge safety structures, and compare your options will help you talk more clearly with your oncology team.
What does it mean to qualify for a glioblastoma clinical trial?
Meeting a trial's inclusion criteria means your tumor type, molecular profile, prior treatment history, and physical condition all fit within the range the study was designed to test. Most glioblastoma trials require a confirmed tissue diagnosis, a minimum performance score, and specific molecular test results before you can be screened for entry. The eligibility rules exist to keep study data consistent and to protect patients whose health profile hasn't been tested at the doses under investigation.
Understanding the three trial phases
Every clinical trial sits in one of three phases. The phase tells you what the researchers are still trying to learn, and that should shape your expectations before you enroll.
- Phase 1: The primary focus is safety. Researchers test whether a new drug or device is safe in humans and find a tolerable dose range. Participant numbers are small. There is no guarantee of direct benefit, and the dose you receive may be lower than what eventually proves effective.
- Phase 2: The drug has cleared a basic safety threshold. Researchers now ask whether it shows early signs of effectiveness and what side effects appear at therapeutic doses. Participant numbers are larger than in Phase 1.
- Phase 3: This phase compares the new treatment head-to-head with the current standard of care in a large group. Regulatory decisions are based on Phase 3 results.
The National Brain Tumor Society's mythbusting guide for brain tumor patients notes that many people assume they will receive only a placebo if assigned to the control arm. In most glioblastoma trials, the control arm receives at least standard-of-care treatment rather than a placebo alone. Knowing this in advance can reduce one of the most common fears about trial participation.
Eligibility criteria decoded: what each requirement actually means
Trial listings on ClinicalTrials.gov use clinical shorthand that can be hard to parse at first. The sections below explain the most common requirements in plain language.
Performance status: KPS and ECOG
Two scales measure how well a patient can carry out daily tasks. The Karnofsky Performance Status (KPS) runs from 0 to 100; a higher score means better function. The Eastern Cooperative Oncology Group (ECOG) scale runs from 0 to 4; a lower score means better function. Most glioblastoma trials require a KPS of 70 or higher, or an ECOG score of 0 or 1. An ASCO-Friends of Cancer Research working group analysis on modernizing trial eligibility criteria found that performance status thresholds significantly affect which patients can access experimental therapies. If a patient's score has dropped because of steroid dependence or neurological deficits, some trials may not be within reach, but the threshold varies by study. A few trials use a lower KPS cutoff of 60.
Molecular markers: MGMT, IDH, and beyond
Many trials require a specific molecular result as a condition for entry. The most common ones you will encounter:
- MGMT promoter methylation status: Trials testing alkylating agents often require a methylated MGMT result, because unmethylated tumors are less likely to respond to that drug class. Some trials are designed specifically for MGMT-unmethylated patients, testing agents aimed at that harder-to-treat group.
- IDH mutation status: The current WHO classification defines glioblastoma as IDH-wildtype. Most GBM trials are built around IDH-wildtype tumors. Trials targeting IDH-mutant gliomas are a separate, smaller category with different eligibility rules.
- Other molecular alterations: Some newer studies screen for EGFR amplification, PTEN loss, or TERT promoter mutations to match patients to targeted agents. These requirements are listed in the inclusion criteria section of the trial listing.
Getting a full molecular workup is the necessary first step before you can realistically screen for most trials. Our article on what your glioblastoma pathology report really means explains how to read each marker and what it tells your care team. For a closer look at how molecular results open or close doors to specific immunotherapy studies, see our companion piece on glioblastoma immunotherapy trials and your molecular profile.
Prior treatment history
Most trials specify exactly which prior therapies are allowed. A common restriction is no prior bevacizumab, because that drug alters tumor vasculature in ways that complicate both safety monitoring and MRI interpretation. Some trials require participants to have already completed the Stupp protocol (surgery plus radiotherapy plus temozolomide). Others are open only at first recurrence. Read the exclusion criteria section of every listing carefully. That is where most disqualifying conditions appear.
Organ function requirements
Trials require minimum blood counts, liver enzyme levels, and kidney function values. The experimental drug must be metabolized safely, and the study team needs a clean baseline to detect drug-related organ changes. If recent bloodwork shows platelet or white cell counts suppressed by prior chemotherapy, a break in treatment may be needed before a screening visit is possible.
Steroid use at enrollment
Many trials cap the corticosteroid dose (usually dexamethasone) that a patient can be taking at the time of entry. High-dose steroids can blunt drug effects and suppress immune function, which is especially relevant for immunotherapy trials. If the patient is on a high dose to manage brain swelling, tapering before the screening visit may be necessary. This requires careful coordination between the trial site and the local treating team.
How to check whether you actually qualify
Reading a trial listing and doing an initial self-assessment is a reasonable starting point. But the only definitive answer comes from the trial site's formal screening process. A practical sequence to follow:
- Use ClinicalTrials.gov or the National Brain Tumor Society's clinical trial finder to build a list of studies matching your diagnosis and current treatment status.
- Filter by phase, location, and (where the tool allows) molecular marker status. Read the full inclusion and exclusion criteria list for every trial you shortlist.
- Bring the shortlist to your neuro-oncologist. Ask them to flag which criteria the patient currently meets, which are uncertain, and which are clearly disqualifying.
- Contact the trial coordinator directly at sites where you pass the initial paper screen. Coordinators handle pre-screening calls regularly and can answer questions before you commit to a visit.
- Request a patient-friendly protocol summary. Coordinators at academic centers can often share one. If you want deeper detail, ask about access to the Investigator's Brochure.
If your current oncologist is not familiar with the trials you have found, or if you are evaluating studies at institutions in another country, having an independent review of your options can save time and reduce the risk of pursuing a study you are unlikely to qualify for. You can consult the Art of Healing Cancer team on what your treatment options actually look like - they can help map the patient's molecular and clinical profile against current open trials before you travel or commit to a specific site.
Our dedicated guide on the clinical trial search strategy for glioblastoma walks through this process in detail, including how to filter by molecular status, recurrence timing, and proximity to treatment centers.
How safety is monitored inside a clinical trial
A common concern is that joining a trial means giving up the protections of standard care. In fact, a regulated trial has layered safeguards that go beyond routine oncology visits.
The National Cancer Institute explains that every trial participant goes through a formal informed-consent process before any study procedure begins. The consent document spells out the study's purpose, what you will be asked to do, known risks, possible benefits, and your rights (including the right to leave at any time without penalty to your standard-care access).
Active safety monitoring operates throughout the study through several distinct mechanisms:
- Data Safety Monitoring Board (DSMB): An independent panel reviews safety data at set intervals. If the trial shows unexpected harm, or if early results are strong enough that keeping participants on the control arm becomes unethical, the board can recommend stopping or modifying the study.
- Institutional Review Board (IRB): The IRB at each site approves the protocol before the study opens and reviews it on an ongoing basis throughout the trial's life.
- Adverse event reporting: Serious side effects must be reported to the FDA, the trial sponsor, and the IRB within defined timeframes. Staff log and track these reports centrally.
- Dose-limiting toxicity rules: In Phase 1 trials, pre-set rules determine when a dose is too harmful to escalate further, and the study pauses for a formal safety review at that point.
Your right to standard-of-care treatment if you withdraw remains intact. Participation is voluntary at every stage of the process.
How to compare multiple trials at once
If more than one trial appears on your shortlist (which is possible when your molecular profile is not unusually narrow), a structured comparison keeps the decision manageable. Focus on the axes that matter most at the patient's specific stage of treatment:
- Phase: A Phase 1 trial carries more uncertainty than Phase 3. That is not a reason to rule it out, but it should factor into your risk threshold and inform your conversation with the oncologist about realistic expectations.
- Mechanism: Is the experimental arm testing a chemotherapy agent, an immunotherapy, a targeted small molecule, or a device-based approach? Some mechanisms have a stronger evidence base from earlier studies than others, and your oncologist can help you assess this.
- Randomization and crossover: Does the study randomly assign participants to arms? If you land in the control arm and the tumor progresses, can you cross over to the experimental treatment? Ask this directly and get a clear answer before you commit.
- Visit burden: How many in-person visits does the protocol require, over how many months? Are any visits inpatient? If the site is far from home, travel and accommodation are real costs to include in the comparison alongside the clinical considerations.
- Participant support: Some industry-sponsored trials cover travel costs, lodging near the study site, or provide the experimental drug at no charge. Ask the trial coordinator this question explicitly during your pre-screening call.
The American Brain Tumor Association's overview of glioblastoma treatment and clinical trials provides useful grounding on how trials fit into the broader treatment picture before you get into the mechanics of any individual study.
Questions to ask before you sign the consent form
The consent visit is a conversation, not a formality. A frightened or rushed signature is not informed consent. These questions are worth raising before you commit:
- What is the probability I am assigned to the control arm rather than the experimental arm?
- If I am in the control arm and the tumor progresses, can I cross over to the experimental treatment?
- What are the most common side effects seen in participants so far, and how have they been managed?
- How does participation affect my eligibility for other trials in the future?
- What happens to my standard-of-care access if I withdraw from the trial mid-study?
- Are there out-of-pocket costs I will need to cover (travel, accommodation, or supportive medications not included in the trial)?
- How will my local oncologist be kept informed throughout the study?
- What data will be collected about me after the trial ends, and for how long?
If the trial coordinator or principal investigator cannot answer these questions clearly, you should note that before you decide whether to proceed.
When to talk to your doctor
Raise clinical trial eligibility with your neuro-oncologist at every staging point (at diagnosis, when adjuvant chemotherapy begins, and again at any sign of progression). The eligibility window for certain trials narrows as treatment history accumulates and exclusion criteria stack up. If your current oncologist does not have active familiarity with open trials in your molecular subgroup, ask for a referral to an academic center or a specialist who runs a dedicated brain tumor board that reviews trial options on a regular basis.
If you are still working out which trials are realistically worth pursuing, you can upload your pathology report, MRI, and treatment history at Glioblastoma Center and request a remote review to help clarify which open studies you are likely to qualify for before you contact any trial site.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.